{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:13:46Z","timestamp":1793459626292,"version":"4.5.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-amyloid antibodies have been shown to reduce cerebral amyloid burden in early Alzheimer\u2019s disease (AD), yet considerable interindividual variability in treatment-associated amyloid reduction has been observed. The biological factors underlying this variability remain unclear. In particular, the influence of aging on amyloid clearance dynamics during anti-amyloid therapy has not been well characterized in real-world clinical settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a prospective observational study of 23 patients with early-stage AD receiving lecanemab who underwent serial\n                      <jats:sup>18<\/jats:sup>\n                      F-flutemetamol amyloid PET at baseline and after 6 and 12 months. Amyloid burden was quantified in centiloid units. Cognitive outcomes were assessed using the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating\u2013Sum of Boxes (CDR-SB). Baseline cerebral perfusion was evaluated using\n                      <jats:sup>123<\/jats:sup>\n                      I-IMP SPECT with three-dimensional stereotactic surface projection (3D-SSP) analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All participants showed reductions in amyloid burden on serial PET; however, the magnitude of reduction varied substantially across individuals. Older patients tended to exhibit larger and more rapid reductions in amyloid burden, whereas younger patients demonstrated more modest decreases despite comparable baseline amyloid levels and standardized dosing. Amyloid reduction at 6 months strongly predicted the magnitude of reduction at 12 months, suggesting that early PET changes capture subsequent amyloid clearance trajectories. Cognitive decline occurred in a subset of patients despite substantial amyloid reduction and was associated with marked baseline temporo-parietal hypoperfusion on SPECT rather than insufficient amyloid removal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world cohort, aging appeared to influence the observable kinetics of amyloid reduction during anti-amyloid therapy. Early serial amyloid PET may provide useful information regarding longer-term amyloid dynamics, while baseline perfusion imaging may help identify patients with substantial downstream neurodegenerative burden who remain at risk for cognitive decline despite amyloid clearance. These findings highlight biological heterogeneity in treatment response and underscore the value of multimodal imaging for monitoring disease-modifying therapies in AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2026.1801267","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:56:16Z","timestamp":1778219776000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Aging modulates amyloid clearance kinetics during anti-amyloid therapy: evidence from real-world serial amyloid PET"],"prefix":"10.3389","volume":"18","author":[{"given":"Tomomichi","family":"Iizuka","sequence":"first","affiliation":[{"name":"Center for Dementia, Fukujuji Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Fukujuji Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kameyama","sequence":"additional","affiliation":[{"name":"AI and Theoretical Image Processing, Research Team for Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer\u2019s disease clinical trials.","volume":"5","author":"Andrews","year":"2019","journal-title":"Alzheimer\u2019s Dement. Trans. Res. Clin. Intervent."},{"key":"B2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s00401-005-1064-y","article-title":"Alzheimer\u2019s pathology influences severity of cerebral amyloid angiopathy.","volume":"110","author":"Attems","year":"2005","journal-title":"Acta Neuropathol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jns.2007.01.013","article-title":"Topographical distribution of cerebral amyloid angiopathy influenced by Alzheimer\u2019s disease pathology.","volume":"257","author":"Attems","year":"2007","journal-title":"J. Neurol. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological staging of Alzheimer-related changes.","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"100160","DOI":"10.1016\/j.jpad.2025.100160","article-title":"Clarity AD: Asian regional analysis of lecanemab in early Alzheimer\u2019s disease.","volume":"12","author":"Chen","year":"2025","journal-title":"J. Prevent. Alzheimer\u2019s Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e2309389120","DOI":"10.1073\/pnas.2309389120","article-title":"A possible mechanism for the enhanced toxicity of \u03b2-amyloid protofibrils in Alzheimer\u2019s disease.","volume":"120","author":"Chen","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B7","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1126\/science.3260686","article-title":"Nonoxidative glucose consumption during neural activity.","volume":"241","author":"Fox","year":"1988","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-\u03b2 pathway in Alzheimer\u2019s disease.","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1017\/s1041610200006359","article-title":"Tracking cognitive decline in Alzheimer\u2019s disease using the mini-mental state examination: A meta-analysis.","volume":"12","author":"Han","year":"2000","journal-title":"Int. Psychogeriatr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/ana.24910","article-title":"FDG metabolism associated with tau\u2013amyloid interaction predicts memory decline.","volume":"81","author":"Hanseeuw","year":"2017","journal-title":"Ann. Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: The amyloid cascade hypothesis.","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e063678","DOI":"10.1002\/alz.063678","article-title":"Neuropathological findings in an Alzheimer\u2019s disease patient treated long-term with lecanemab.","volume":"18","author":"Honig","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"key":"B13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer\u2019s disease: An updated hypothetical model of dynamic biomarkers.","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","article-title":"Association of pre-mortem [11C]PIB-PET centiloid values with post-mortem Alzheimer\u2019s disease pathology.","volume":"15","author":"La Joie","year":"2019","journal-title":"Alzheimer\u2019s Dement."},{"key":"B15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/alzrt255","article-title":"Perspectives on future Alzheimer therapies: Amyloid-\u03b2 protofibrils as a new target for immunotherapy with BAN2401.","volume":"6","author":"Lannfelt","year":"2014","journal-title":"Alzheimer\u2019s Res. Therapy"},{"key":"B16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1474-4422(04)00853-1","article-title":"PET imaging of amyloid in Alzheimer\u2019s disease.","volume":"3","author":"Nordberg","year":"2004","journal-title":"Lancet Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"14745","DOI":"10.1073\/pnas.0905127106","article-title":"Structure\u2013neurotoxicity relationships of amyloid \u03b2-protein oligomers.","volume":"106","author":"Ono","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B18","doi-asserted-by":"publisher","first-page":"103950","DOI":"10.1016\/j.mcn.2024.103950","article-title":"Disease-modifying effects of mAb158 in aged Tg2576 mice.","volume":"130","author":"Rizoska","year":"2024","journal-title":"Mol. Cell. Neurosci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","article-title":"The molecular pathology of Alzheimer\u2019s disease.","volume":"6","author":"Selkoe","year":"1991","journal-title":"Neuron"},{"key":"B20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.neurobiolaging.2025.06.003","article-title":"Biological age acceleration in Alzheimer\u2019s disease modulates relative cortical to medial temporal lobe neurodegeneration.","volume":"153","author":"Sreepada","year":"2025","journal-title":"Neurobiol. Aging"},{"key":"B21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, placebo-controlled phase 2b proof-of-concept clinical trial of lecanemab in early Alzheimer\u2019s disease.","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimer\u2019s Res. Therapy"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212949","article-title":"Lecanemab in early Alzheimer\u2019s disease.","volume":"388","author":"Van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: A prospective cohort study.","volume":"12","author":"Villemagne","year":"2013","journal-title":"Lancet Neurol."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1801267\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:56:17Z","timestamp":1778219777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1801267\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":23,"alternative-id":["10.3389\/fnagi.2026.1801267"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2026.1801267","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1801267"}}